查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2012892

生物可吸收聚合物市場：依產品、形態、製造流程、材料類型、應用和最終用戶分類－2026-2032年全球市場預測

Bioresorbable Polymers Market by Product, Form, Manufacturing Process, Material Type, Application, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，生物可吸收聚合物市場價值將達到 10.9 億美元，到 2026 年將成長至 11.9 億美元，複合年成長率為 11.90%，到 2032 年將達到 22.6 億美元。

主要市場統計數據
基準年 2025 10.9億美元
預計年份：2026年 11.9億美元
預測年份 2032 22.6億美元
複合年成長率 (%) 11.00%

生物可吸收聚合物是一種能夠在生物環境中安全分解，並在指定壽命內保持其功能性能的材料。近年來，聚合物化學和加工技術的進步使得人們能夠精確控制分解速率，提高生物相容性，並建構兼具治療和結構功能的多功能結構。因此，這些材料正在成為醫療設備、藥物傳輸和組織工程等領域的重要基礎技術，而這些領域先前一直以永久性植入和不可分解系統為主導。

同時，轉化科學與先進製造技術的融合正在催生纖維、薄膜、微粒和奈米結構，為臨床醫生和產品開發人員拓展了設計可能性。越來越多的臨床前和臨床證據為這些進展提供了支持，這些證據闡明了安全性特徵和性能標準。因此，相關人員如今正處於一個關鍵的十字路口。生物可吸收解決方案的技術可行性已趨於成熟，而主要挑戰正轉向如何將其與法規結構、穩健的供應鏈以及臨床認可相整合。

本導言為全面探討材料類型、加工方法、特定應用需求以及加速推廣應用並降低營運風險的策略措施奠定了基礎。後續章節將為參與生物可吸收聚合物生態系的組織提供綜合說明，內容涵蓋技術演進、政策影響、市場細分洞察、區域差異、競爭資訊和實用建議。

聚合物化學、精密製造和臨床需求的進展如何匯聚，重新定義生物可吸收醫用材料的未來發展方向。

生物可吸收聚合物領域正經歷一場變革，其驅動力來自材料創新、精密製造和跨領域合作。在材料層面，可用的化學成分範圍已從傳統的聚乳酸體系擴展到包括共聚物和特殊骨架結構。這些材料具有針對特定應用的分解性能和功能基團適用性。這種擴展的材料工具包使開發人員能夠針對特定的臨床情況（例如承重整形外科應用和精細的血管內治療）最佳化材料的機械性能和分解特性。

評估 2025 年美國關稅變化對企業營運和供應鏈調整的影響及其策略意義。

政策和貿易環境正對生物可吸收聚合物價值鏈產生實際影響，美國近期實施的將於2025年生效的關稅措施改變了中間原料、特種聚合物和精密設備的進口趨勢。這些政策調整迫使製造商重新評估其籌資策略，短期影響主要集中在依賴國際原料供應的供應商以及依賴進口擠出、射出成型和微加工設備的資本財的供應商。

從詳細的細分觀點展示產品形式、製造流程、材料化學特性和應用需求如何影響策略優先順序。

透過對產品、形態、製造流程、材料類型、應用和最終用戶等各個維度進行分析，細分市場分析能夠揭示潛在的機會和性能促進因素。從產品角度來看，該領域涵蓋纖維、薄膜、微粒和奈米材料，每種材料都有獨特的功能優勢。纖維提供定向強度和孔隙率控制；薄膜提供阻隔功能和可塑性；微粒可用作注射或植入式藥物儲存載體；奈米材料則支持細胞層面的靶向相互作用。同時，形態（液體、粉末或固體）決定了處理方法、滅菌方案和合適的下游製造技術，從而影響該解決方案可整合到哪些臨床工作流程中。

美洲、歐洲、中東和非洲以及亞太地區的區域趨勢正在影響監管路徑、製造地決策和臨床試驗。

地理因素在美洲、歐洲、中東和非洲以及亞太地區的技術採納、監管趨勢和供應鏈發展中發揮重要作用。在美洲，臨床界和醫保體系支持能夠降低再次手術和長期照護成本的創新，這推動了人們對可吸收植入和局部給藥解決方案的興趣。法規環境強調安全性和臨床證據，促進了強力的臨床試驗和機構間夥伴關係，以加速實用化。

競爭格局洞察，重點介紹成熟企業、利基創新者和學術衍生公司如何塑造其商業化和合作策略。

生物可吸收聚合物領域的競爭格局呈現出多元化的特點，既有特種聚合物供應商，也有整合材料專業知識的醫療設備製造商，還有專注於新型化學品和設計結構的主導新興參與企業。成熟企業憑藉其規模優勢、成熟的生產平台和豐富的監管經驗，致力於開發符合高合規性要求的應用，例如心血管和整形外科植入。這些成熟企業通常強調品管系統、可追溯性和廣泛的臨床數據，以提升市場接受度。

經營團隊的策略重點是將聚合物科學的進步轉化為擴充性的、經臨床檢驗的、商業性可行性的解決方案。

產業領導者應優先考慮一系列切實可行的舉措，將科學潛力與實際應用結合，加速價值實現。首先，應投資進行可靠的材料表徵和體外-體內相關性研究，將分解曲線與性能終點連結起來。這些數據將降低監管方面的不確定性，並增強臨床醫生的信心。其次，應推行模組化生產策略，在維持材料和製程控制的前提下，實現從試驗規模到商業化生產規模的擴展。採用品質源自於設計 (QbD) 原則可以降低變異性，並加快醫療設備認證流程。

結合專家訪談、文獻整合和比較技術評估的綜合調查方法，確保了基於證據的實用見解。

本研究採用綜合分析方法，結合對材料科學家、醫療設備開發人員、臨床研究人員和供應鏈專家的訪談，以及對同行評審文獻和監管文件的系統性回顧。原始數據經過結構化處理，旨在捕捉技術成熟度、製造限制、臨床偏好和採購考慮。訪談主題在不同資訊來源間進行了交叉檢驗，以確認研究結果的有效性並識別通用趨勢。

摘要強調了綜合實施在將生物可吸收聚合物的創新轉化為持續的臨床影響方面所發揮的關鍵作用。

生物可吸收聚合物在材料科學、臨床需求和生產能力三大領域的交會點佔據戰略地位。化學、加工技術和協作轉化生態系統的進步降低了技術壁壘，並擴大了其在臨床上的實際應用範圍。然而，為了充分發揮這些材料的潛力，並確保其即使在大規模應用中也能保持穩定的性能，需要在證據收集、供應鏈設計和與監管機構合作等方面採取周密的計劃。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：生物可吸收聚合物市場：依產品分類

  • 纖維
  • 電影
  • 細顆粒物
  • 奈米材料

第9章：生物可吸收聚合物市場：依形式分類

  • 液體
  • 粉末
  • 固體的

第10章：生物可吸收聚合物市場：依製造製程分類

  • 吹塑成型
  • 擠壓
  • 射出成型

第11章：生物可吸收聚合物市場：依材料類型分類

  • 聚烷氫化物
  • 聚己內酯（PCL）
  • 聚乙醇酸（PGA）
  • 聚羥基烷酯（PHA）
  • 聚乳酸（PLA）

第12章：生物可吸收聚合物市場：依應用領域分類

  • 藥物輸送系統
    • 緩釋製劑
    • 標靶特異性遞送系統
  • 醫療植入
    • 心血管支架
    • 整形外科植入
  • 組織工程
    • 鷹架設計
    • 幹細胞支架
  • 創傷治療裝置
    • 黏合劑解決方案
    • 包紮材料

第13章：生物可吸收聚合物市場：依最終用戶分類

  • 生技公司
  • 醫院和診所
  • 製藥公司
  • 研究機構

第14章：生物可吸收聚合物市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：生物可吸收聚合物市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章：生物可吸收聚合物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國生物可吸收聚合物市場

第18章：中國生物可吸收聚合物市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Advanced Polymer Materials Inc.
  • Ashland Inc.
  • Corbion NV
  • DSM Biomedical
  • DURECT Corporation
  • Evonik Industries AG
  • Foster Corporation
  • Groupe PCAS
  • KLS Martin Group
  • Merck KGaA
  • Mitsubishi Chemical Group Corporation
  • NatureWorks LLC
  • Novamont SpA
  • Poly-Med Incorporated
  • REVA Medical, LLC
  • SEQENS SAS
  • Teijin Limited
  • Zeus Industrial Products, Inc.
Product Code: MRR-437D45957EE1

The Bioresorbable Polymers Market was valued at USD 1.09 billion in 2025 and is projected to grow to USD 1.19 billion in 2026, with a CAGR of 11.00%, reaching USD 2.26 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.09 billion
Estimated Year [2026] USD 1.19 billion
Forecast Year [2032] USD 2.26 billion
CAGR (%) 11.00%

Bioresorbable polymers represent a class of materials engineered to degrade safely within biological environments while delivering functional performance during their intended service life. Recent advances in polymer chemistry and processing techniques have enabled precisely tuned degradation kinetics, enhanced biocompatibility, and multifunctional constructs that serve therapeutic and structural roles. As a result, these materials are emerging as critical enablers across medical devices, drug delivery, and tissue engineering, where permanent implants or nondegradable systems previously dominated.

Concurrently, translational science is converging with advanced manufacturing to produce architectures at the fiber, film, micro-particle, and nanoscale levels, expanding the design space for clinicians and product developers. These developments are supported by a growing corpus of preclinical and clinical evidence that clarifies safety profiles and performance benchmarks. Therefore, stakeholders now face a pivotal moment: the technical plausibility of bioresorbable solutions has matured, and the primary challenges shift toward integration with regulatory frameworks, supply chain robustness, and clinical acceptance.

This introduction sets the stage for a nuanced exploration of material classes, processing modalities, application-specific demands, and strategic actions that can accelerate adoption while mitigating operational risk. The succeeding sections synthesize technological shifts, policy impacts, segmentation intelligence, geographic variations, competitive positioning, and pragmatic recommendations for organizations engaged in the bioresorbable polymer ecosystem.

How advances in polymer chemistry, precision manufacturing, and clinical demand are converging to redefine the future pathways for resorbable medical materials

The landscape for bioresorbable polymers is undergoing transformative shifts driven by material innovation, precision manufacturing, and cross-disciplinary collaboration. At the material level, the palette of available chemistries has broadened beyond traditional polylactide systems to include copolymers and specialty backbones that afford tailored degradation and functional group compatibility. This expanded material toolkit enables developers to optimize mechanical properties and degradation profiles for specific clinical contexts, such as load-bearing orthopedic applications or delicate vascular interventions.

In manufacturing, additive and advanced molding techniques are moving from prototyping to regulated production, enabling architected scaffolds and device features previously unattainable with conventional methods. Such process innovation interacts with material science to reduce variability and enhance reproducibility, which in turn eases regulatory review pathways. Additionally, there is a growing emphasis on scalable sterilization approaches and quality-by-design paradigms that align with industry expectations for consistency.

Healthcare delivery trends are also reshaping demand: clinicians increasingly prioritize devices that reduce secondary procedures and long-term foreign body complications, which supports interest in resorbable alternatives for stents, fixation devices, and localized drug depots. Moreover, cross-sector collaborations-linking academic groups, clinical investigators, and industry developers-accelerate translational pathways by combining domain expertise, shared biobanking resources, and translational trial networks. Collectively, these shifts point toward an ecosystem that is more modular, evidence-driven, and capable of bringing complex bioresorbable solutions to market with improved predictability.

Assessment of the operational and supply chain adjustments prompted by United States tariff changes in 2025 and their strategic implications

Policy and trade environments have a tangible influence on the bioresorbable polymers value chain, and recent tariff measures introduced in the United States in 2025 altered import dynamics for intermediate feedstocks, specialty polymers, and precision equipment. These policy adjustments have prompted manufacturers to reassess sourcing strategies, with near-term effects concentrated on suppliers dependent on international raw-material flows or on capital goods imported for extrusion, injection molding, and microfabrication equipment.

In response, some manufacturers have diversified supply bases or engaged in contract manufacturing closer to end markets to mitigate border-related headwinds. Others have accelerated qualification of alternative polymer grades and localized suppliers to reduce exposure to tariff-induced cost volatility. The cumulative operational effect includes tighter inventory management, renegotiated supplier contracts, and increased investment in logistic resiliency. While larger multinational producers have absorbed a portion of the impact through integrated supply networks, smaller and mid-sized producers felt acute pricing and lead-time pressures that influenced project timelines and partnership negotiations.

Importantly, these tariff-driven adjustments also stimulated conversations around vertical integration for critical intermediates and enhanced domestic capacity planning. Regulatory alignment and procurement policies that favor locally supplied materials can further shape adoption pathways. For decision-makers, the key takeaway lies in evaluating supplier risk, maintaining flexible sourcing strategies, and anticipating procurement timelines that account for potential trade-policy volatility.

Deep segmentation perspective showing how product forms, manufacturing routes, material chemistries, and application demands inform strategic prioritization

Segmentation analysis reveals nuanced opportunities and performance drivers when examined across product, form, manufacturing process, material type, application, and end-user dimensions. When evaluated on the product axis, the field encompasses fibers, films, micro-particles, and nanomaterials, each offering distinct functional advantages: fibers provide directional strength and porosity control, films enable barrier and conformability functions, micro-particles facilitate injectable or implantable drug depots, and nanomaterials support targeted interactions at the cellular level. In parallel, the form factor-liquid, powder, or solid-dictates handling, sterilization choices, and suitable downstream fabrication approaches, influencing which clinical workflows a solution can enter.

Manufacturing processes span blow molding, extrusion, and injection molding, and each presents trade-offs among throughput, geometric complexity, and material compatibility. Designers select processes to match device geometry, scale, and precision needs, recognizing that process-induced stresses and thermal histories can materially affect degradation behavior. Material type remains a primary determinant of performance, with chemistries such as polyanhydrides, polycaprolactone, polyglycolic acid, polyhydroxyalkanoate, and polylactic acid offering diverse degradation kinetics and mechanical profiles that align with specific clinical demands.

Application-driven segmentation illustrates where value accrues: drug delivery systems, including controlled-release formulations and target-specific vehicles, exploit resorbable matrices to localize therapy and minimize systemic exposure. Medical implants, notably cardiovascular stents and orthopedic implants, leverage temporary mechanical support followed by safe resorption to eliminate long-term foreign body presence. Tissue engineering efforts focus on scaffold designs and stem cell scaffolding to guide regeneration, while wound healing devices such as adhesive solutions and bandaging materials use transient material presence to promote repair. Finally, end-user categories-biotechnology companies, hospitals and clinics, pharmaceutical companies, and research institutes-shape adoption through differing procurement cycles, regulatory expectations, and clinical deployment pathways. Together, these segmentation lenses inform prioritization of R&D investment, manufacturing capacity, and commercialization strategies.

Regional dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific shaping regulatory pathways, manufacturing footprint decisions, and clinical adoption

Geographic considerations play a significant role in technology adoption, regulatory trajectories, and supply chain architecture across the Americas, Europe Middle East & Africa, and Asia-Pacific regions. In the Americas, clinical communities and reimbursement structures favor innovations that reduce repeat interventions and long-term care costs, which supports interest in resorbable implants and localized drug delivery solutions. The regulatory environment emphasizes safety and clinical evidence, prompting robust clinical trial engagement and institutional partnerships that can accelerate translation.

Across Europe, the Middle East & Africa, regulatory harmonization initiatives and centralized review processes in some jurisdictions facilitate pathway clarity but also require comprehensive technical documentation and post-market surveillance commitments. Clinical preference patterns and procurement mechanisms vary, leading companies to adopt regionally tailored market-entry strategies. Similarly, EMEA procurement often stresses lifecycle cost and clinical outcomes, reinforcing the value proposition of devices that demonstrably reduce long-term complications.

The Asia-Pacific region exhibits a heterogeneous but rapidly maturing ecosystem, with significant manufacturing capacity and growing clinical trial activity. Several economies in the region are investing in domestic polymer and medical-device capabilities, which creates both competitive advantages and collaborative opportunities for global players. Supply chain proximity in Asia-Pacific can reduce lead times for regional manufacturers, while regulatory modernization in many markets is creating clearer clinical pathways for novel resorbable solutions. Taken together, these regional dynamics inform decisions about manufacturing footprints, clinical partnerships, and regulatory engagements to optimize adoption and patient outcomes.

Competitive landscape insights highlighting how incumbents, niche innovators, and academic spinouts are shaping commercialization and partnership strategies

Competitive dynamics within the bioresorbable polymer landscape are characterized by a mix of specialty polymer suppliers, device manufacturers with integrated materials expertise, and research-driven entrants focused on novel chemistries or architected structures. Established firms leverage scale, validated manufacturing platforms, and regulatory experience to pursue high-compliance applications such as cardiovascular and orthopedic implants. These incumbents often emphasize quality management systems, traceability, and extensive clinical datasets to support market acceptance.

At the same time, smaller and niche players contribute innovation in formulation science, advanced processing, and application-specific adaptations. Their agility enables rapid iteration on material blends and surface modifications that can address unmet clinical needs. Collaboration between specialized material developers and device manufacturers is increasingly common, yielding co-development agreements, licensing arrangements, and strategic partnerships that align material properties with device function.

Furthermore, academic spin-outs and research institutes remain important sources of disruptive concepts, particularly in areas like stimulus-responsive degradation, hierarchical scaffold architectures, and integration of biologics. For organizations navigating this competitive landscape, differentiation often hinges on demonstrable clinical benefit, manufacturability at scale, and a clear regulatory strategy. Strategic alliances, targeted IP protection, and investments in manufacturing qualification are prudent mechanisms to convert technical advantage into commercial traction.

Actionable strategic priorities for executives to convert polymer science advancements into scalable, clinically validated, and commercially viable solutions

Industry leaders should prioritize a set of pragmatic actions that bridge scientific promise with operational execution to accelerate value realization. First, invest in robust materials characterization and in vitro-to-in vivo correlation studies that link degradation profiles to performance endpoints. Such data will reduce regulatory uncertainty and support clinician confidence. Second, pursue modular manufacturing strategies that allow scaling from pilot to commercial volumes while preserving material and process control; adopting quality-by-design principles can reduce variability and speed device qualification.

Third, develop supply chain resilience through diversified sourcing, strategic supplier partnerships, and where appropriate, localized production for critical intermediates to mitigate trade-policy or logistic disruptions. Fourth, structure clinical evidence generation to demonstrate meaningful patient outcomes and economic value; partnering with healthcare systems and forming registry networks can produce longitudinal data that reinforce reimbursement positions. Fifth, cultivate cross-functional teams that integrate regulatory, clinical, manufacturing, and commercial expertise early in development to avoid late-stage rework and to align product features with adoption drivers.

Finally, consider IP strategies and collaborative models that unlock complementary capabilities, whether through licensing, joint ventures, or co-development agreements. By executing these recommendations in parallel, organizations can reduce time-to-clinic, lower deployment risk, and strengthen the commercial case for advanced bioresorbable solutions.

Comprehensive methodology combining expert interviews, literature synthesis, and comparative technical evaluation to ensure evidence-based, actionable insights

This research synthesis integrates primary interviews with materials scientists, device developers, clinical investigators, and supply chain specialists, complemented by a systematic review of peer-reviewed literature and regulatory documentation. Primary inputs were structured to capture technology readiness, manufacturing constraints, clinical preferences, and procurement considerations. Interview themes were triangulated across sources to validate findings and identify convergent trends.

Analytical methods included comparative evaluation of material classes against application-specific performance criteria, process compatibility assessments for common manufacturing routes, and scenario analysis of supply chain disruptions. Emphasis was placed on cross-validation: technical claims from developers were checked against independent bench reports and clinical trial registries where available. Regulatory considerations were derived from public agency guidance, product clearances, and post-market surveillance summaries to ensure alignment with current expectations.

The research approach also prioritized transparency in assumptions and data provenance. Wherever practical, limitations and knowledge gaps are identified to guide future investigation and to support evidence-based decision-making by stakeholders considering investments, partnerships, or clinical programs in the bioresorbable polymers domain.

Concluding synthesis emphasizing the pivotal role of integrated execution in translating bioresorbable polymer innovations into durable clinical impact

Bioresorbable polymers occupy a strategic intersection of materials science, clinical need, and manufacturing capability. Advances in chemistries, processing technologies, and collaborative translational ecosystems have reduced technical barriers and expanded the portfolio of viable clinical applications. However, realizing the full potential of these materials requires deliberate action across evidence generation, supply chain design, and regulatory engagement to ensure consistent performance at scale.

Stakeholders that integrate rigorous materials characterization, scalable manufacturing practices, and targeted clinical evidence programs will be best positioned to capture clinical and economic value. Policy dynamics and regional differences in regulatory and procurement practices further emphasize the need for localized strategies and flexible supply networks. Ultimately, organizations that align scientific innovation with operational discipline and strategic partnerships will create the most durable pathways to adoption, delivering patient-centric solutions that reduce intervention burden and improve long-term outcomes.

This conclusion underscores a pragmatic view: technical readiness has advanced substantially, but strategic execution remains the differentiator between prototype promise and widespread clinical impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Bioresorbable Polymers Market, by Product

  • 8.1. Fibers
  • 8.2. Films
  • 8.3. Micro-Particles
  • 8.4. Nanomaterials

9. Bioresorbable Polymers Market, by Form

  • 9.1. Liquid
  • 9.2. Powder
  • 9.3. Solid

10. Bioresorbable Polymers Market, by Manufacturing Process

  • 10.1. Blow Molding
  • 10.2. Extrusion
  • 10.3. Injection Molding

11. Bioresorbable Polymers Market, by Material Type

  • 11.1. Polyanhydrides
  • 11.2. Polycaprolactone (PCL)
  • 11.3. Polyglycolic Acid (PGA)
  • 11.4. Polyhydroxyalkanoate (PHA)
  • 11.5. Polylactic Acid (PLA)

12. Bioresorbable Polymers Market, by Application

  • 12.1. Drug Delivery Systems
    • 12.1.1. Controlled Release Formulations
    • 12.1.2. Target-Specific Vehicles
  • 12.2. Medical Implants
    • 12.2.1. Cardiovascular Stents
    • 12.2.2. Orthopedic Implants
  • 12.3. Tissue Engineering
    • 12.3.1. Scaffold Designs
    • 12.3.2. Stem Cell Scaffolding
  • 12.4. Wound Healing Devices
    • 12.4.1. Adhesive Solutions
    • 12.4.2. Bandaging Materials

13. Bioresorbable Polymers Market, by End-User

  • 13.1. Biotechnology Companies
  • 13.2. Hospitals and Clinics
  • 13.3. Pharmaceutical Companies
  • 13.4. Research Institutes

14. Bioresorbable Polymers Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Bioresorbable Polymers Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Bioresorbable Polymers Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Bioresorbable Polymers Market

18. China Bioresorbable Polymers Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Advanced Polymer Materials Inc.
  • 19.6. Ashland Inc.
  • 19.7. Corbion NV
  • 19.8. DSM Biomedical
  • 19.9. DURECT Corporation
  • 19.10. Evonik Industries AG
  • 19.11. Foster Corporation
  • 19.12. Groupe PCAS
  • 19.13. KLS Martin Group
  • 19.14. Merck KGaA
  • 19.15. Mitsubishi Chemical Group Corporation
  • 19.16. NatureWorks LLC
  • 19.17. Novamont S.p.A.
  • 19.18. Poly-Med Incorporated
  • 19.19. REVA Medical, LLC
  • 19.20. SEQENS SAS
  • 19.21. Teijin Limited
  • 19.22. Zeus Industrial Products, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIORESORBABLE POLYMERS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BIORESORBABLE POLYMERS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY MANUFACTURING PROCESS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY MATERIAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES BIORESORBABLE POLYMERS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA BIORESORBABLE POLYMERS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY FIBERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY FIBERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY FIBERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY FILMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY FILMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY FILMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY MICRO-PARTICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY MICRO-PARTICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY MICRO-PARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY NANOMATERIALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY NANOMATERIALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY NANOMATERIALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY LIQUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY LIQUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY POWDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY POWDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY POWDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY SOLID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY SOLID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY SOLID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY BLOW MOLDING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY BLOW MOLDING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY BLOW MOLDING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY EXTRUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY EXTRUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY EXTRUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY INJECTION MOLDING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY INJECTION MOLDING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY INJECTION MOLDING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY POLYANHYDRIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY POLYANHYDRIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY POLYANHYDRIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY POLYCAPROLACTONE (PCL), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY POLYCAPROLACTONE (PCL), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY POLYCAPROLACTONE (PCL), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY POLYGLYCOLIC ACID (PGA), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY POLYGLYCOLIC ACID (PGA), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY POLYGLYCOLIC ACID (PGA), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY POLYHYDROXYALKANOATE (PHA), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY POLYHYDROXYALKANOATE (PHA), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY POLYHYDROXYALKANOATE (PHA), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY POLYLACTIC ACID (PLA), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY POLYLACTIC ACID (PLA), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY POLYLACTIC ACID (PLA), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY DRUG DELIVERY SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY DRUG DELIVERY SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY DRUG DELIVERY SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY DRUG DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY CONTROLLED RELEASE FORMULATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY CONTROLLED RELEASE FORMULATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY CONTROLLED RELEASE FORMULATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY TARGET-SPECIFIC VEHICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY TARGET-SPECIFIC VEHICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY TARGET-SPECIFIC VEHICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY MEDICAL IMPLANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY MEDICAL IMPLANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY MEDICAL IMPLANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY MEDICAL IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY CARDIOVASCULAR STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY CARDIOVASCULAR STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY CARDIOVASCULAR STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY ORTHOPEDIC IMPLANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY ORTHOPEDIC IMPLANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY ORTHOPEDIC IMPLANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY TISSUE ENGINEERING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY TISSUE ENGINEERING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY TISSUE ENGINEERING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY SCAFFOLD DESIGNS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY SCAFFOLD DESIGNS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY SCAFFOLD DESIGNS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY STEM CELL SCAFFOLDING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY STEM CELL SCAFFOLDING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY STEM CELL SCAFFOLDING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY WOUND HEALING DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY WOUND HEALING DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY WOUND HEALING DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY WOUND HEALING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY ADHESIVE SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY ADHESIVE SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY ADHESIVE SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY BANDAGING MATERIALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY BANDAGING MATERIALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY BANDAGING MATERIALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS BIORESORBABLE POLYMERS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS BIORESORBABLE POLYMERS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS BIORESORBABLE POLYMERS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS BIORESORBABLE POLYMERS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS BIORESORBABLE POLYMERS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS BIORESORBABLE POLYMERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS BIORESORBABLE POLYMERS MARKET SIZE, BY DRUG DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS BIORESORBABLE POLYMERS MARKET SIZE, BY MEDICAL IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS BIORESORBABLE POLYMERS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS BIORESORBABLE POLYMERS MARKET SIZE, BY WOUND HEALING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS BIORESORBABLE POLYMERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA BIORESORBABLE POLYMERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA BIORESORBABLE POLYMERS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA BIORESORBABLE POLYMERS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA BIORESORBABLE POLYMERS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA BIORESORBABLE POLYMERS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA BIORESORBABLE POLYMERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA BIORESORBABLE POLYMERS MARKET SIZE, BY DRUG DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA BIORESORBABLE POLYMERS MARKET SIZE, BY MEDICAL IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA BIORESORBABLE POLYMERS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA BIORESORBABLE POLYMERS MARKET SIZE, BY WOUND HEALING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA BIORESORBABLE POLYMERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA BIORESORBABLE POLYMERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA BIORESORBABLE POLYMERS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA BIORESORBABLE POLYMERS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA BIORESORBABLE POLYMERS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA BIORESORBABLE POLYMERS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA BIORESORBABLE POLYMERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA BIORESORBABLE POLYMERS MARKET SIZE, BY DRUG DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA BIORESORBABLE POLYMERS MARKET SIZE, BY MEDICAL IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA BIORESORBABLE POLYMERS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA BIORESORBABLE POLYMERS MARKET SIZE, BY WOUND HEALING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA BIORESORBABLE POLYMERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA BIORESORBABLE POLYMERS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA BIORESORBABLE POLYMERS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA BIORESORBABLE POLYMERS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA BIORESORBABLE POLYMERS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA BIORESORBABLE POLYMERS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA BIORESORBABLE POLYMERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA BIORESORBABLE POLYMERS MARKET SIZE, BY DRUG DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA BIORESORBABLE POLYMERS MARKET SIZE, BY MEDICAL IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA BIORESORBABLE POLYMERS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA BIORESORBABLE POLYMERS MARKET SIZE, BY WOUND HEALING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA BIORESORBABLE POLYMERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE BIORESORBABLE POLYMERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE BIORESORBABLE POLYMERS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE BIORESORBABLE POLYMERS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE BIORESORBABLE POLYMERS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE BIORESORBABLE POLYMERS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE BIORESORBABLE POLYMERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE BIORESORBABLE POLYMERS MARKET SIZE, BY DRUG DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE BIORESORBABLE POLYMERS MARKET SIZE, BY MEDICAL IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE BIORESORBABLE POLYMERS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE BIORESORBABLE POLYMERS MARKET SIZE, BY WOUND HEALING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE BIORESORBABLE POLYMERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST BIORESORBABLE POLYMERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST BIORESORBABLE POLYMERS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST BIORESORBABLE POLYMERS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST BIORESORBABLE POLYMERS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST BIORESORBABLE POLYMERS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST BIORESORBABLE POLYMERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST BIORESORBABLE POLYMERS MARKET SIZE, BY DRUG DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST BIORESORBABLE POLYMERS MARKET SIZE, BY MEDICAL IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST BIORESORBABLE POLYMERS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST BIORESORBABLE POLYMERS MARKET SIZE, BY WOUND HEALING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST BIORESORBABLE POLYMERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA BIORESORBABLE POLYMERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA BIORESORBABLE POLYMERS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA BIORESORBABLE POLYMERS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA BIORESORBABLE POLYMERS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA BIORESORBABLE POLYMERS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA BIORESORBABLE POLYMERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA BIORESORBABLE POLYMERS MARKET SIZE, BY DRUG DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA BIORESORBABLE POLYMERS MARKET SIZE, BY MEDICAL IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA BIORESORBABLE POLYMERS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA BIORESORBABLE POLYMERS MARKET SIZE, BY WOUND HEALING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA BIORESORBABLE POLYMERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC BIORESORBABLE POLYMERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC BIORESORBABLE POLYMERS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC BIORESORBABLE POLYMERS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC BIORESORBABLE POLYMERS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC BIORESORBABLE POLYMERS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC BIORESORBABLE POLYMERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC BIORESORBABLE POLYMERS MARKET SIZE, BY DRUG DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC BIORESORBABLE POLYMERS MARKET SIZE, BY MEDICAL IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC BIORESORBABLE POLYMERS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC BIORESORBABLE POLYMERS MARKET SIZE, BY WOUND HEALING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC BIORESORBABLE POLYMERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN BIORESORBABLE POLYMERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN BIORESORBABLE POLYMERS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN BIORESORBABLE POLYMERS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN BIORESORBABLE POLYMERS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN BIORESORBABLE POLYMERS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN BIORESORBABLE POLYMERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN BIORESORBABLE POLYMERS MARKET SIZE, BY DRUG DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN BIORESORBABLE POLYMERS MARKET SIZE, BY MEDICAL IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN BIORESORBABLE POLYMERS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN BIORESORBABLE POLYMERS MARKET SIZE, BY WOUND HEALING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN BIORESORBABLE POLYMERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 206. GCC BIORESORBABLE POLYMERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. GCC BIORESORBABLE POLYMERS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 208. GCC BIORESORBABLE POLYMERS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 209. GCC BIORESORBABLE POLYMERS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 210. GCC BIORESORBABLE POLYMERS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. GCC BIORESORBABLE POLYMERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. GCC BIORESORBABLE POLYMERS MARKET SIZE, BY DRUG DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 213. GCC BIORESORBABLE POLYMERS MARKET SIZE, BY MEDICAL IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 214. GCC BIORESORBABLE POLYMERS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 215. GCC BIORESORBABLE POLYMERS MARKET SIZE, BY WOUND HEALING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 216. GCC BIORESORBABLE POLYMERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION BIORESORBABLE POLYMERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION BIORESORBABLE POLYMERS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION BIORESORBABLE POLYMERS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION BIORESORBABLE POLYMERS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION BIORESORBABLE POLYMERS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION BIORESORBABLE POLYMERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION BIORESORBABLE POLYMERS MARKET SIZE, BY DRUG DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION BIORESORBABLE POLYMERS MARKET SIZE, BY MEDICAL IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION BIORESORBABLE POLYMERS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION BIORESORBABLE POLYMERS MARKET SIZE, BY WOUND HEALING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION BIORESORBABLE POLYMERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS BIORESORBABLE POLYMERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS BIORESORBABLE POLYMERS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS BIORESORBABLE POLYMERS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS BIORESORBABLE POLYMERS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS BIORESORBABLE POLYMERS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS BIORESORBABLE POLYMERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS BIORESORBABLE POLYMERS MARKET SIZE, BY DRUG DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS BIORESORBABLE POLYMERS MARKET SIZE, BY MEDICAL IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS BIORESORBABLE POLYMERS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS BIORESORBABLE POLYMERS MARKET SIZE, BY WOUND HEALING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS BIORESORBABLE POLYMERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 239. G7 BIORESORBABLE POLYMERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 240. G7 BIORESORBABLE POLYMERS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 241. G7 BIORESORBABLE POLYMERS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 242. G7 BIORESORBABLE POLYMERS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 243. G7 BIORESORBABLE POLYMERS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. G7 BIORESORBABLE POLYMERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 245. G7 BIORESORBABLE POLYMERS MARKET SIZE, BY DRUG DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 246. G7 BIORESORBABLE POLYMERS MARKET SIZE, BY MEDICAL IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 247. G7 BIORESORBABLE POLYMERS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 248. G7 BIORESORBABLE POLYMERS MARKET SIZE, BY WOUND HEALING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 249. G7 BIORESORBABLE POLYMERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 250. NATO BIORESORBABLE POLYMERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 251. NATO BIORESORBABLE POLYMERS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 252. NATO BIORESORBABLE POLYMERS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 253. NATO BIORESORBABLE POLYMERS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 254. NATO BIORESORBABLE POLYMERS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. NATO BIORESORBABLE POLYMERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 256. NATO BIORESORBABLE POLYMERS MARKET SIZE, BY DRUG DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 257. NATO BIORESORBABLE POLYMERS MARKET SIZE, BY MEDICAL IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 258. NATO BIORESORBABLE POLYMERS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 259. NATO BIORESORBABLE POLYMERS MARKET SIZE, BY WOUND HEALING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 260. NATO BIORESORBABLE POLYMERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 261. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES BIORESORBABLE POLYMERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES BIORESORBABLE POLYMERS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 264. UNITED STATES BIORESORBABLE POLYMERS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES BIORESORBABLE POLYMERS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES BIORESORBABLE POLYMERS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. UNITED STATES BIORESORBABLE POLYMERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES BIORESORBABLE POLYMERS MARKET SIZE, BY DRUG DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES BIORESORBABLE POLYMERS MARKET SIZE, BY MEDICAL IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED STATES BIORESORBABLE POLYMERS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES BIORESORBABLE POLYMERS MARKET SIZE, BY WOUND HEALING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES BIORESORBABLE POLYMERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 273. CHINA BIORESORBABLE POLYMERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 274. CHINA BIORESORBABLE POLYMERS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 275. CHINA BIORESORBABLE POLYMERS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 276. CHINA BIORESORBABLE POLYMERS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 277. CHINA BIORESORBABLE POLYMERS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. CHINA BIORESORBABLE POLYMERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 279. CHINA BIORESORBABLE POLYMERS MARKET SIZE, BY DRUG DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA BIORESORBABLE POLYMERS MARKET SIZE, BY MEDICAL IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 281. CHINA BIORESORBABLE POLYMERS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA BIORESORBABLE POLYMERS MARKET SIZE, BY WOUND HEALING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA BIORESORBABLE POLYMERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)